GPC3 and neoplasm: Indeed, the clinical efficacy of GPC3-targeted therapies, particularly CAR-T cells, may be limited by the immunosuppressive tumor microenvironment, which impairs T cell infiltration and persistence, as well as by the risk of severe immune-related adverse events such as cytokine release syndrome and on-target, off-tumor toxicity.